Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.37 |
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712238 | 1.00 | LPL (0.41) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL15824989 | 0.84 | GSK3A (0.30) | GSK3AGSK3B | |
| SCHEMBL15555994 | 0.83 | DGAT1 (0.37) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL29535422 | 0.83 | LPL (0.43) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL2696361 | 0.83 | LPL (0.43) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL18895034 | 0.81 | LPL (0.42) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL2427096 | 0.81 | LPL (0.42) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL11910717 | 0.81 | DGAT1 (0.36) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL10380169 | 0.80 | LPL (0.41) | LPLLIPGEGFRAAK1PDGFRB | |
| SCHEMBL2066738 | 0.80 | PDGFRB (0.46) | LPLLIPGEGFRAAK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4543887-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250129053-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-24 | — | — | US | disclosed |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| CN-118103362-A | Herbicidal imidazole compounds | 先正达农作物保护股份公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150315472-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150315472-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150183801-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| EP-2858988-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-20150065743-A1 | METHODS FOR PRODUCING BORYLATED ARENES | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2015-03-05 | — | — | US | disclosed |
| WO-2013171640-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071428-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | LPL 2477/4885LIPG 1167/4885EGFR 98/4885 |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | LPL 2477/4885LIPG 1167/4885EGFR 98/4885 |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | LPL 4312/4885LIPG 1708/4885EGFR 592/4885 |
| US-20150315472-A1 | LIQUID-CRYSTALLINE MEDIUM | FES, SOST, POF1B | LPL 3442/4885LIPG 4093/4885EGFR 3180/4885 |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | LPL 2477/4885LIPG 1167/4885EGFR 98/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | LPL 2736/4885LIPG 1417/4885EGFR 518/4885 |
| US-20250129053-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | DDT, H1-0, H1-3 | LPL 4512/4885LIPG 4513/4885EGFR 2800/4885 |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | LPL 2477/4885LIPG 1167/4885EGFR 98/4885 |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | LPL 3792/4885LIPG 4301/4885EGFR 1730/4885 |
| US-20150183801-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | LPL 4725/4885LIPG 3936/4885EGFR 22/4885 |
| US-20150065743-A1 | METHODS FOR PRODUCING BORYLATED ARENES | BOLA2; BOLA2B, EMD, BRI3BP | LPL 3687/4885LIPG 3278/4885EGFR 631/4885 |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | LPL 2477/4885LIPG 1167/4885EGFR 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.